This study is a double-blind, placebo-controlled, randomized, outpatient clinical investigation in adult patients with moderate-to-severe chronic plaque psoriasis. Each patient receives double-blind treatment for 12 weeks, with a follow up period of 6 weeks after the last dose.
MM-093, Merrimack’s lead product, is a recombinant version of human alpha-fetoprotein.
The study is being conducted at the University of Utah with Dr Gerald Krueger as the principle investigator, and at the Texas Dermatology Research Institute in Dallas with Dr Alan Menter as the principle investigator.
“Results from this pilot study will be available in late summer this year,” said Robert Mulroy, president & CEO. The development of MM-093 is focused on diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis – indications for which published and proprietary preclinical data provide a compelling rationale for its use, and in which significant unmet medical needs still exist.”